Thalidomide and immunomodulatory drugs in the treatment of cancer

被引：23

作者：

Bamias, A ^{[1
]}

Dimopoulos, MA ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Clin Therapeut, Athens 14561, Greece

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2005年 / 14卷 / 01期

关键词：

angiogenesis; cancer; CC-4047; CC-5013; ImiD; myeloma; thalidomide;

D O I：

10.1517/13543784.14.1.45

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies. Multiple studies have confirmed its activity in multiple myeloma, alone or combined with dexamethasone and/or chemotherapy as first- or second-line treatment. In addition, it may reduce the need for transfusions in patients with myelofibrosis or myelodysplastic syndromes. The activity of thalidomide in solid tumours is less prominent. The most promising results have been reported in Kaposi's sarcoma, malignant melanoma and prostate cancer, especially when it is combined with chemotherapy. Recently, thalidomide analogues (immunomodulatory drugs), with higher immunomodulatory activity and different toxicity profile, have been developed. They have already shown promising activity in multiple myeloma and are currently being evaluated in clinical studies.

引用

页码：45 / 55

页数：11

共 89 条

[61] Thalidomide as initial therapy for early-stage myeloma [J].

Rajkumar, SV ;

Gertz, MA ;

Lacy, MQ ;

Dispenzieri, A ;

Fonseca, R ;

Geyer, SM ;

Iturria, N ;

Kumar, S ;

Lust, JA ;

Kyle, RA ;

Greipp, PR ;

Witzig, TE .

LEUKEMIA, 2003, 17 (04) :775-779

[62] Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma [J].

Rajkumar, SV ;

Hayman, S ;

Gertz, MA ;

Dispenzieri, A ;

Lacy, MQ ;

Greipp, PR ;

Geyer, S ;

Iturria, N ;

Fonseca, R ;

Lust, JA ;

Kyle, RA ;

Witzig, TE .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4319-4323

[63]

RAJKUMAR SV, 2004, P ASCO, P558

[64] Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes [J].

Raza, A ;

Meyer, P ;

Dutt, D ;

Zorat, F ;

Lisak, L ;

Nascimben, F ;

du Randt, M ;

Kaspar, C ;

Goldberg, C ;

Loew, J ;

Dar, S ;

Gezer, S ;

Venugopal, P ;

Zeldis, J .

BLOOD, 2001, 98 (04) :958-965

[65]

Richardson P, 2002, BLOOD, V100, p104A

[66] Thalidomide: Emerging role in cancer medicine [J].

Richardson, P ;

Hideshima, T ;

Anderson, K .

ANNUAL REVIEW OF MEDICINE, 2002, 53 :629-657

[67] Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma [J].

Richardson, PG ;

Schlossman, RL ;

Weller, E ;

Hideshima, T ;

Mitsiades, C ;

Davies, F ;

LeBlanc, R ;

Catley, LP ;

Doss, D ;

Kelly, K ;

McKenney, M ;

Mechlowicz, J ;

Freeman, A ;

Deocampo, R ;

Rich, R ;

Ryoo, JJ ;

Chauhan, D ;

Balinski, K ;

Zeldis, J ;

Anderson, KC .

BLOOD, 2002, 100 (09) :3063-3067

[68] The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children [J].

Rovelli, A ;

Arrigo, C ;

Nesi, F ;

Balduzzi, A ;

Nicolini, B ;

Locasiulli, A ;

Vassallo, E ;

Miniero, R ;

Uderzo, C .

BONE MARROW TRANSPLANTATION, 1998, 21 (06) :577-581

[69] Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma [J].

Schey, SA ;

Fields, P ;

Bartlett, JB ;

Clarke, IA ;

Ashan, G ;

Knight, RD ;

Streetly, M ;

Dalgleish, AG .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3269-3276

[70] Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis [J].

Seldin, DC ;

Choufani, EB ;

Dember, LM ;

Wiesman, JF ;

Berk, JL ;

Falk, RH ;

O'Hara, C ;

Fennessey, S ;

Finn, KT ;

Wright, DG ;

Skinner, M ;

Sanchorawala, V .

CLINICAL LYMPHOMA, 2003, 3 (04) :241-246

← 1 2 3 4 5 6 7 8 9 →